Are you a healthcare professional?

EOS-Inflammation-logo
No, I am not a healthcare professional
AstraZeneca Logo
  • Home
  • EOS Education
    • EOS Education
    • EOS Inflammation
    • SEA
    • EGPA
    • HES
  • Latest Science
  • Resource Library

EOS-Inflammation-logo

Welcome!

This hub of educational material is designed to provide an overview of eosinophil-driven diseases to help you consider the importance of eosinophilic inflammation in your clinical decisions.

Although eosinophils are present in a range of eosinophil-associated diseases, there are some in which activated eosinophils perpetuate eosinophilic inflammation and mediate organ dysfunction through interactions with structural tissue cells and other immune cells.1–5 In these conditions where eosinophils may drive disease, such as severe eosinophilic asthma (SEA), eosinophilic granulomatosis and polyangiitis (EGPA), and hypereosinophilic syndrome (HES), unresolved eosinophilic inflammation can result in potentially irreversible reduced organ/tissue function.1,3,4,6

The aim of this hub is to provide an understanding of how eosinophilic inflammation can drive pathology in eosinophil-driven diseases and act as a predictor of outcomes.1–3,7,8

EOS Education

Learn more about eosinophilic inflammation and eosinophil-driven diseases (SEA, EGPA, and HES)


 

Explore this topic

Latest Science

See the latest data relating to eosinophilic inflammation and its role in driving disease and predicting poor outcomes

Explore this topic

Resource Library

Visit the resource library for a comprehensive list of downloadable assets from across the website

 

View resources
Back to top

EGPA, eosinophilic granulomatosis and polyangiitis; EOS, eosinophil; HES, hypereosinophilic syndrome; SEA, severe eosinophilic asthma.

 

  1. Quirce S, et al. Front Immunol 2023;14:1192284
  2. Vatrella A, et al. Biomedicines 2022;10:2181
  3. Arnold IC, Munitz A. Nat Rev Immunol 2024;24:858–877
  4. Jacobsen EA, et al. Annu Rev Immunol 2021;39:719–757
  5. Klion AD. Blood 2015;126:1069–1077
  6. Valent P, et al. Allergy 2023;78:47–59
  7. Jackson DJ, et al. Eur Respir Rev 2022;31:210150
  8. Fagni F, et al. Front Med (Lausanne) 2021;8:627776
AZ-logo

EOSInflammation.com has been
developed by AstraZeneca.
For healthcare professionals only.
© 2026 AstraZeneca

  • Privacy Notice
  • Cookie Notice
  • Legal Statement
  • Contact Us

Veeva ID: Z4-82610
Date of preparation: June 2026